Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. VSports app下载.

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2020 Jan 8;10(1):30.
doi: 10.3390/diagnostics10010030.

The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer

Natalya Apanovich  1 , Maria Peters  2 , Pavel Apanovich  1 , Danzan Mansorunov  1 , Anna Markova  2 , Vsevolod Matveev  2 , Alexander Karpukhin  1
Affiliations

"VSports手机版" The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer

Natalya Apanovich et al. Diagnostics (Basel). .

Abstract

The molecular prognostic markers of metastasis are important for personalized approaches to clear cell renal cell carcinoma (ccRCC) treatment but markers for practical use are still missing. To address this gap we studied the expression of ten genes-CA9, NDUFA4L2, VWF, IGFBP3, BHLHE41, EGLN3, SAA1, CSF1R, C1QA, and FN1-through RT-PCR, in 56 ccRCC patients without metastases and with metastases. All of these, excluding CSF1R, showed differential and increased (besides SAA1) expression in non-metastasis tumors. The gene expression levels in metastasis tumors were decreased, besides CSF1R, FN1 (not changed), and SAA1 (increased) VSports手机版. There were significant associations of the differentially expressed genes with ccRCC metastasis by ROC analysis and the Fisher exact test. The association of the NDUFA4L2, VWF, EGLN3, SAA1, and C1QA expression with ccRCC metastasis is shown for the first time. The CA9, NDUFA4L2, BHLHE4, and EGLN3 were distinguished as the strongest candidates for ccRCC metastasis biomarkers. We used an approach that presupposed that the metastasis marker was the expression levels of any three genes from the selected panel and received sensitivity (88%) and specificity (73%) levels with a relative risk of RR > 3. In conclusion, a panel of selected genes-the candidates in biomarkers of ccRCC metastasis-was created for the first time. The results might shed some light on the ccRCC metastasis processes. .

Keywords: gene expression; markers; renal cancer V体育安卓版. .

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Heat map of the expression of 20 genes in the clear cell renal cell carcinoma (ccRCC) samples. At the top of the figure, the stages of cancer development for each sample are shown.
Figure 2
Figure 2
Relative gene expression (RQ) in groups with metastases (●) and without metastases (●). Gene expression values are presented on a logarithmic scale. The line marks the median.
Figure 2
Figure 2
Relative gene expression (RQ) in groups with metastases (●) and without metastases (●). Gene expression values are presented on a logarithmic scale. The line marks the median.
See this image and copyright information in PMC

References

    1. Vuyyala S., Gandhi S., Kuechle J.B., George S. Complete Remission of Bone Metastases in Renal Cell Carcinoma with Nivolumab. Cureus. 2019;11:5531. doi: 10.7759/cureus.5531. - DOI - PMC - PubMed
    1. Kim S.H., Park B., Hwang E.C., Hong S.-H., Jeong C.W., Kwak C., Byun S.S., Chung J. Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma. Front. Oncol. 2019;9:859. doi: 10.3389/fonc.2019.00859. - DOI - PMC - PubMed
    1. Frees S.K., Kamal M.M., Nestler S., Levien P.M., Bidnur S., Brenner W., Thomas C., Jaeger W., Thüroff J.W., Roos F.C. Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy. Int. J. Urol. 2018;26:385–390. doi: 10.1111/iju.13882. - DOI - PubMed
    1. Escudier B., Porta C., Schmidinger M., Rioux-Leclercq N., Bex A., Khoo V., Grünwald V., Gillessen S., Horwich A., ESMO Guidelines Committee Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 2019;30:706–720. doi: 10.1093/annonc/mdz056. - DOI - PubMed
    1. Marconi L., Dabestani S., Lam T.B., Hofmann F., Stewart F., Norrie J., Bex A., Bensalah K., Canfield S.E., Hora M., et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur. Urol. 2016;69:660–673. doi: 10.1016/j.eururo.2015.07.072. - DOI - PubMed

LinkOut - more resources